News & Updates
Filter by Specialty:
Sotrovimab may reduce COVID-19 disease progression
The pan-sarbecovirus monoclonal antibody sotrovimab appears to reduce the risk of COVID-19 disease progression in high-risk patients, according to interim results of the phase III COMET-ICE* trial.
Sotrovimab may reduce COVID-19 disease progression
23 Nov 2021
Hypertension-related CVD rates rise from 1990 to 2019
For three decades, hypertension-related cardiovascular disease (CVD) burden in young adults has substantially rose, with spatiotemporal and sexual heterogeneity, according to a study. Middle-income countries bear the heaviest burden, particularly men.
Hypertension-related CVD rates rise from 1990 to 2019
23 Nov 2021
Exercise SBP tied to cardiovascular disease risk
Exercise systolic blood pressure (SBP) is linked to several cardiovascular risk factors, which tend to be worse in individuals with a hypertensive response to exercise (HRE), reveals a study.
Exercise SBP tied to cardiovascular disease risk
23 Nov 2021
Guselkumab yields durable benefit in biologic-naïve PsA patients
The interleukin (IL)-23p19-subunit inhibitor guselkumab appears to produce improvements in multiple disease domains of psoriatic arthritis (PsA) with no unexpected safety findings through 2 years of treatment in biologic-naïve patients, according to the phase III DISCOVER-2 trial.